1. Home
  2. PMN vs PPCB Comparison

PMN vs PPCB Comparison

Compare PMN & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$7.23

Market Cap

23.5M

Sector

Health Care

ML Signal

HOLD

PPCB

Propanc Biopharma Inc.

N/A

Current Price

$0.53

Market Cap

20.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PMN
PPCB
Founded
2004
2007
Country
Canada
Australia
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.5M
20.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PMN
PPCB
Price
$7.23
$0.53
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$72.67
N/A
AVG Volume (30 Days)
31.5K
268.9K
Earning Date
11-12-2025
02-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.27
$0.58
52 Week High
$39.75
$145.46

Technical Indicators

Market Signals
Indicator
PMN
PPCB
Relative Strength Index (RSI) 58.74 N/A
Support Level $8.00 N/A
Resistance Level $8.73 N/A
Average True Range (ATR) 0.56 0.00
MACD -0.39 0.00
Stochastic Oscillator 9.86 0.00

Price Performance

Historical Comparison
PMN
PPCB

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: